UniQure is looking to jump-start a phase 1/2 trial for a Huntington's disease gene therapy after a safety monitoring board gave the go-ahead for dosing to resume.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,